Lung cancer
Oncology· 20 reviewed drugs· 84505 cited findings behind them
What the regulatory reviews cover
This library contains regulatory review documents for several drugs indicated for lung cancer. These include Keytruda, indicated for first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC) in combination with chemotherapy, which showed an Objective Response Rate of 74.4% in the pembrolizumab arm versus 51.9% in the placebo arm (Keytruda FDA Review, p.132). Opdivo, for first-line treatment of metastatic NSCLC, demonstrated a Median Overall Survival of 15.7 months (Bristol-Myers Squibb Company — Opdivo FDA Review, p.65). Enhertu, for unresectable or metastatic HER2-positive NSCLC, reported an Objective response rate (ORR) of 60.3 (Daiichi Sankyo Company, Limited — Enhertu FDA Review, p.18). Yervoy, in combination with nivolumab and chemotherapy for first-line treatment of metastatic or recurrent NSCLC, showed an OS improvement of 3 months (Bristol-Myers Squibb Company — Yervoy EMA EPAR variation ass, p.147).
Other drugs in the library with lung cancer indications include Krazati, Tevimbra, Augtyro, TEPMETKO, Lumakras, Tecentriq, Rybrevant, Imdelltra, Alecensa, Zepzelca, Zykadia, Tabrecta, and Imjudo. It is important to note that these drugs were studied in different clinical trials with varying designs and patient populations. Therefore, the reported figures are not directly comparable head-to-head across different drugs.
The drugs — one cited result each
| Keytruda Merck & Co., Inc. | Objective Response Rate (pembrolizumab arm): 74.4 Keytruda FDA Review, p.132 |
| Opdivo Bristol-Myers Squibb Company | Median Overall Survival: 15.7 months Bristol-Myers Squibb Company — Opdivo FDA Review (NDA/BLA 12, p.65 |
| Enhertu Daiichi Sankyo Company, Limited | Objective response rate (ORR): 60.3 Daiichi Sankyo Company, Limited — Enhertu FDA Review (BLA761, p.18 |
| Yervoy Bristol-Myers Squibb Company | OS improvement: 3 months Bristol-Myers Squibb Company — Yervoy EMA EPAR variation ass, p.147 |
| Abraxane Bristol-Myers Squibb Company | 3452 cited findings on the drug page → |
| Taxotere Sanofi | 3154 cited findings on the drug page → |
| Krazati Bristol-Myers Squibb Company | Overall response rate (ORR): 43% Krazati FDA Review (NDA216340, p.18 |
| Tevimbra BeOne Medicines Ltd. | median PFS2: 13.1 Months BeOne Medicines Ltd. — Tevimbra EMA EPAR variation assessmen, p.57 |
| Augtyro Bristol-Myers Squibb Company | Confirmed Overall Response Rate: 79 Bristol-Myers Squibb Company — Augtyro FDA Review (NDA/BLA 2, p.32 |
| TEPMETKO Merck KGaA | PFS (months) in overall ITT: 8.6 Merck KGaA — Tepmetko FDA Review (NDA214096, ORIG 1, 2021), p.163 |
| Lumakras Amgen Inc. | Median OS (Pembrolizumab vs docetaxel, TPS >= 50%): 14.9 vs 8.2 Amgen Inc. — Lumakras FDA Review (NDA214665, ORIG 1, 2021), p.30 |
| Tecentriq Roche Holding AG | Median overall survival (months): 12.6 GENENTECH INC — Tecentriq FDA Summary Review (NDA/BLA 761041, p.4 |
| Rybrevant Johnson & Johnson | 1758 cited findings on the drug page → |
| Retevmo Eli Lilly and Company | 1566 cited findings on the drug page → |
| Imdelltra Amgen Inc. | Median OS (tarlatamab): 13.6 Amgen Inc. — Imdelltra FDA Review (NDA/BLA 761344, 2026), p.337 |
| Alecensa Roche Holding AG | Stratified HR for DFS (alectinib vs chemotherapy, Stage II-IIIA): 0.24 Roche Holding AG — Alecensa EMA EPAR variation assessment re, p.37 |
| Zepzelca Mar S A | 1323 cited findings on the drug page → |
| Zykadia Novartis AG | 1290 cited findings on the drug page → |
| Tabrecta Novartis AG | 1234 cited findings on the drug page → |
| Imjudo AstraZeneca PLC | 1057 cited findings on the drug page → |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Oncology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.